Health officials said that at least 7 states reported high levels of illness, with cases also rising in other parts of the country; a group of Senate Democrats demanded answers about the shortage of nirsevimab, a new respiratory syncytial virus (RSV) drug; Pentagon officials told Congress that eliminating per- and polyfluorinated substances would undermine military readiness.
With flu season underway, health officials said that at least 7 states reported high levels of illness, and cases are rising in other parts of the country, according to the Associated Press. The CDC posted new data on Friday, which showed high activity in Louisiana, Alabama, Florida, Georgia, Mississippi, New Mexico, and South Carolina; cases were also high in the District of Columbia and Puerto Rico. Additionally, flu activity was found to be moderate but rising in Arkansas, California, Maryland, New Jersey, New York City, North Carolina, Tennessee, and Texas. So far this fall, the CDC estimated at least 780,000 flu illnesses, 8000 hospitalizations, and 490 deaths.
A group of Senate Democrats demanded answers about the shortage of nirsevimab, a new respiratory syncytial virus (RSV) drug, according to The Hill. Nirsevimab, marketed as Beyfortus, is a monoclonal antibody that allows babies to directly receive antibodies to prevent severe RSV disease; shortages of the drug have been occurring since its approval in August due to unprecedented demands. Within a letter led by Senator Tammy Duckworth (D, Illinois) sent Friday, lawmakers asked manufacturers Sanofi and AstraZeneca for more information about the current supply, why they were so unprepared for the demand, and when the companies first became aware of the shortage. The letter was cosigned by Senate Democrats Kirsten Gillibrand (New York), Ed Markey (Massachusetts), Ron Wyden (Oregon), Elizabeth Warren (Massachusetts), Richard Blumenthal (Connecticut), and Jon Ossoff (Georgia).
As regulators propose restrictions on per- and polyfluorinated substances (PFAS) due to associated health conditions, Pentagon officials told Congress that eliminating the chemicals would undermine military readiness, according to KFF Health News. PFAS are known as forever chemicals as they do not break down in the environment and can build up in the human body, causing health problems like cancer. Because of this, Congress has pressured the Department of Defense (DoD) to stop using PFAS. Despite related health concerns, the DoD relies on hundreds, if not thousands, of weapons and products, like batteries, uniforms, and microelectronics that contain PFAS. Consequently, the DoD delivered a report to Congress, which was made public by the American Chemistry Council last month, that pushed back against their requests, claiming regulations against PFAS would greatly impact national security and DoD’s ability to fulfill its mission.
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen